Coya Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Coya Therapeutics, Inc. (COYA) on April 2, 2026, reporting events occurring on March 29, 2026. The filing addresses significant changes to the Company's Board of Directors and executive leadership.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on corporate governance changes and compensatory arrangements.
Material Changes
- Departure of Executive Chairman: Dr. Howard Berman resigned from the Board and his position as Executive Chairman, effective April 1, 2026.
- Appointment of New Director: Mark H. Pavao was appointed as an independent director (Class III) effective April 1, 2026, to fill the vacancy left by Dr. Berman.
Compensatory Arrangements and Management Commentary
Dr. Howard Berman Separation Terms:
- Bonus: Entitled to a prorated 2026 annual bonus at 100% of target, payable on the next regular payroll date.
- Health Benefits: Company will pay or waive COBRA premiums through March 31, 2027, or until eligibility for other coverage.
- Equity: Unvested stock options will continue to vest for 12 months post-separation. The post-termination exercise period for vested options is extended to the two-year anniversary of the separation date.
- Restrictions: No additional severance is provided beyond these terms. The agreement includes a general release of claims and non-disparagement provisions.
Mark H. Pavao Appointment Terms:
- Equity Grant: Granted an option to purchase 10,000 shares of common stock at the closing price on the grant date. Options vest one year from the grant date, contingent on continued service.
- Compensation: Will receive standard non-employee director fees as outlined in the 2025 Form 10-K.
- Committees: No committee assignments at the time of appointment; assignments to be considered later.
Investor Verification Checklist
- Verify the full text of the Separation and Release Agreement (Exhibit 10.1) for specific definitions of the "Separation Date" and any clawback provisions.
- Confirm the exact exercise price of the stock options granted to Mr. Pavao based on the Nasdaq closing price on April 1, 2026.
- Review the Company's 2025 Form 10-K to understand the standard fee structure for non-employee directors applicable to Mr. Pavao.
- Monitor future filings for the announcement of Mr. Pavao's committee assignments and any interim CEO appointment if Dr. Berman's departure leaves a leadership gap.